3 completed, 1 recruiting, 1 unknown. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow CF102: new trials by email Literature Review of CF102 trials Research Report on CF102
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Namodenoson Treatment of Advanced Pancreatic Cancer Namodenoson 25mg - Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 2 | Recruiting | Can-Fite BioPharma | 20 | 2024-11-10 | 2025-01-31 |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Namodenoson, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Can-Fite BioPharma | 114 | 2021-12-10 | 2024-07-31 |
| A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease CF102, Placebo - Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Can-Fite BioPharma | 60 | 2017-11-27 | 2020-03-17 |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) CF102, Placebo - Hepatocellular Carcinoma | Phase 2 | Completed | Can-Fite BioPharma | 78 | 2014-09-01 | 2022-10-04 |
| A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma CF102 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Can-Fite BioPharma | 19 | 2009-02-01 | 2022-05-17 |
Carcinoma, Hepatocellular (2) · Non-alcoholic Fatty Liver Disease (2) · Pancreatic Neoplasms (1)
Israel (5) · Bulgaria (2) · Romania (2) · Serbia (2) · Bosnia and Herzegovina (1) · Moldova (1) · United States (1)
Michael H Silverman, MD (4) · Michael H Silverman (1) · Salomon M Stemmer, MD (1) · Salomon Shtemmer, MD (1)